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ABSTRACT 
 
Sanghvi, Saagar Kamlesh. M.S. Department of Neuroscience, Cell Biology & 
Physiology, Wright State University 2012. Effect of Rat Strain and Stereotactic 
Coordinates on Infarct Volume. 
 
Ischemic stroke makes up 87% of all hospital-admitted stroke cases annually; the primary 
treatment for these cases is intravenous administration of tPA within a 3.5 hour window 
from stroke onset. A long-term delayed ischemic stroke treatment proposed by this study 
was a combination of the pharmaceuticals Fluoxetine (SSRI), Simvastatin (statin), and 
ascorbic acid (Vitamin C). 51 adult rat subjects (10-12 months of age; 44 Sprague 
Dawley, 7 Long Evans) were given a combination of the drugs for 31 days. Drugs were 
given through voluntary oral administration via sugar cookie-dough balls to reduce 
inhibition of neurogenesis through stress-related glucocorticoid production. Drug 
combinations were as follows: FSA - 5 mg/kg fluoxetine, 0.5 mg/kg simvastatin and 20 
mg/kg ascorbic acid; FS - 5 mg/kg fluoxetine, 0.5 mg/kg simvastatin; and the vehicle 
control. Endothelin-induced cortical stroke was administered using 2 different set of 
coordinates relative to bregma: Group 1 - (AP: 0.0 mm, ML: -2.5 mm) and (AP +1.5 mm; 
ML: -2.5 mm); Group 2 - (AP: 0.0 mm, ML: -2.5mm) and (AP +2.3; ML -2.5 mm). To 
analyze functional deficit, rats were subject to Montoya Staircase functional test once 
pre-stroke and twice post-stroke, and the Forelimb Asymmetry functional test once pre-
stroke and thrice post-stroke. Results showed that Long Evans rats sustain a significantly 
larger infarct volume compared to Sprague Dawley rats using Group 2 coordinates; 
Group 1 cortical injection coordinates produced a larger infarct than Group 2 coordinates 
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in FSA Sprague Dawley rats; drug treatment showed no effect on total infarct volume, 
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As the 2nd leading cause of death in the world surpassed only by ischemic heart 
disease, Cerebrovascular disease in the US claims 133,000 lives every year (NSA, 2012). 
Almost 800,000 strokes will occur nationwide this year alone – once every 40 seconds, 
causing a fatality approximately every 4 minutes (NSA, 2012).  Stroke is defined as an 
acute condition: blood supply to the brain is altered in affected areas due to a vascular 
blockage or hemorrhaging vessel, and the resulting tissue ischemia can cause cell death 
within minutes of stroke onset. However, with 7,000,000 adult stroke survivors – two-
thirds of who endure some type of stroke-related disability everyday – the effects of 
stroke are chronic (VL, 2012).  Visual impairments, paralysis, aphasia, and other sensory 
and motor deficits can result from brain tissue damage. American patients' average direct 
cost of care for 90 days post-stroke is greater than $15,000, with additional costs from 
rehabilitation and preventative medications that can last years. The US currently spends 
$43 billion on stroke a year (Di Carlo, 2009). Considering three-fourths of all stroke 
patients are older than 65 years, a population expected to grow 200% worldwide over the 
next 30 years, the healthcare system itself faces a long-term economic problem in 
addition to the growing human cost (AHA, 2012). 
 
What is a stroke and how is it treated?   
There are two defined types of stroke– ischemic and hemorrhagic. Ischemic 
strokes account for the vast majority (87%) of all stroke cases (AHA, 2012). This 
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condition results from gradual atherosclerotic plaque and fatty-acid deposit accumulation 
in a brain blood vessel. These blockages either originate at the site (thrombotic stroke) or 
are transported from another location in the body vasculature (embolic stroke). Risk 
factors for an ischemic attack include hypertension, high cholesterol, diabetes, obesity, 
alcoholism, and conditions such fibromuscular dysplasia and atrial fibrillation (NSA, 
2012). Less common hemorrhagic strokes result from a blood vessel rupture in or on the 
surface of the brain; treatments associated with this condition promote blood coagulation 
and reducing brain pressure. 
The primary treatment for an ischemic stroke attack is administration of 
recombinant Tissue Plasminogen Activator (rt-PA) within a 3.5-hour window of stroke 
onset. tPA, a natural human enzyme found in endothelial cells lining blood vessels, 
activates plasminogen in order to dissolve blood clots. rt-PA is most commonly injected 
through a vein in the arm, but can also be delivered directly to the infarct site via catheter. 
Up to 70% of hospital stroke admissions are for ischemic stroke; however, only 3.5 to 8% 
of these patients are able to receive the rt-PA clot-buster within the 3.5-hour 
administration window. Most admitted ischemic stroke patients must seek an alternate 
method of treatment (Mayo Clinic, 2010). 
The vast majority of diagnosed ischemic stroke patients are prescribed aspirin for 
for its blood-thinning effect, primarily to prevent another stroke. Other blood-thinning 
drugs such as warfarin (Coumadin), heparin and clopidogrel (Plavix) are also options for 
preventative stroke treatment, but the presence of aneurysms or other risk factors for 
hemorrhagic stroke must be taken heavily into consideration (Mayo Clinic, 2010). 
Invasive surgical procedures such as stent angioplasties and carotid endarterectomies are 
 3 
useful only for a small percentage of stroke patients. Most stroke patients have numerous 
surgical complications and therefore increased probabilities of triggering another 
ischemic attack, weak vessels hemorrhaging, or recurrent vessel stenosis. Considering 
that 25% of victims will have a repeat incidence within 5 years, and more than 50% of all 
ischemic stroke victims will die in 8 years, a need for an effective long-term stroke 
treatment aside from prescribing aspirin remains (ISC, 2012). 
 
A Drug-Cocktail for Delayed Treatment of Ischemic Stroke 
A treatment model that increases the window of time available to administer rt-
PA or aides in developing a long-term treatment solution needs to either diminish the 
onset of ischemic stroke or curb the effects of stroke after onset. Treatment strategies 
examining various elements of the ischemic stroke cascade, including calcium channels 
and glutamate receptors, have either been unsuccessful or are currently undergoing trials 
(Shabitz, 2006). A probable strategy for treating neural sensory and motor deficits caused 
by stroke, however, can be related to curing the damaged brain tissue itself. Growth of 
neurons and glial cells have been linked to various growth factors that may also play a 
role in repairing damaged tissue (Allen, 2006).  Up-regulating factors involved in 
neurogenesis or growth factor production may play a role in treating brain deficits related 
to stroke. 
Two germinal niches have been identified as regions of neurogenesis: the 
subventricular zone (SVZ) and the subgranular zone (SGZ). The SVZ is found adjacent 
to the lateral ventricles of the forebrain (see Figure 1), and the SGZ is found within the 
dentate gyrus of the hippocampus. Self-renewing, multipotent cells that have been shown 
to create various neural cells are found in both regions; however, the SVZ is the largest 
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shown to be the largest 
neurogenic niche in the adult brain (Quinoneshinojosa, 2007). 
The subventricular zone (SVZ) contains multipotent neural stem cells (type B 
cells) that have been 
identified as the neural 
progenitor cell (Gonzales-
Perez, 2012). This self-
renewing astrocytic type B 
cell can then generate self-
renewing “transit-
amplifying” progenitor 
cells (type C cells) (see 
Figure 2). These type C 
Figure 1.  (A) Rat brain: Neurogenic Centers, Rostral Migratory Stream leading to 
olfactory bulb  Image from Scientopia.org 
(B) Human Brain: Subventricular Zone (SVZ), adjacent to the lateral 
ventricles Image from Oscar Arias-Carrión, 2008  
Figure 2.  Self-renewing multipotent neural stem cells (type B) can differentiate into 
transit-amplifying cells (type C).  Self-renewing type C cells can differentiate into 




cells may then differentiate into various migrating neuroblasts (type A cells), that develop 
into end cells such as neurons, oligodendrocytes, and astrocytes. Type B cells are made 
up of Type B1 and Type B2 astrocytes. Type B1 cells associate closely with the 
ependymal layer through adherens and gap junctions, and the brain parenchymal blood 
vessels and basal lamina. Their apical processes extend to the ventricular surface 
(Gonzales-Perez, 2012). These associations have suggested that type B cells may play a 
role in neurogenesis through direct interaction and supporting growth. The newly formed 
type A neuroblasts migrate to the olfactory bulb along the rostral migratory pathway.  
Type B1 cells express molecular markers associated with their astrocytic morphology, a 
few of which are glial fibrillary acidic protein (GFAP), nestin, and vimentin. Type C cells 
can be identified using epidermal growth factor receptors (EGFR). Type A-cell 
neuroblasts can be identified with doublecortin (Zhang, 2004). 
Growth factors associated with neurogenesis include epidermal growth factor 
(EGF) and the family of neurotrophins, specifically brain-derived neurotrophin (BDNF). 
EGF has been shown to support proliferation of SVZ neural progenitors such as type B1 
cells (Gonzales-Perez, 2009); BDNF has been shown to support existing neurons while 
promoting neurogenesis and synaptogenesis (Mattson, 2008). 
The primary difference between the human and rodent subventricular zone is that 
in humans, the 2nd SVZ layer (hypocellular gap) is devoid of cell bodies, and 3rd layer 
astrocytes are organized as a ribbon of GFAP+ cells that do not contact the ependymal 
layer (see Figure 3). In both species, the SVZ 1st layer is made of multi-ciliated 
ependymal cells that regulate substance such as cerebrospinal fluid at the ventricular 




 A drug cocktail 
developed to repair 
damaged brain tissue can 
work through promoting 
neurogenesis or the 
production of growth 
factors shown to support 
neurogenesis. Statins 
have been commonly 
used for reducing cholesterol levels in preventing various artery diseases; studies have 
also established pleiotropic effects of statins which include inducing neurogenesis and 
synaptogenesis in the hippocampal dentate gyrus (Lu et al, 2007; Chen et al, 2003) up-
regulation of endothelial nitric oxide synthase (eNOS) and tPA activity, and increased 
levels of brain-derived neurotrophic factor (BDNF) in the ischemic boundary zone after 
stroke. After phosphorylation and subsequent activation of eNOS, statins have been 
shown to increase the amount of NO, though the exact mechanism is not fully understood 
(Datar et al, 2010). eNOS has also been shown to up-regulate BDNF (Wu et al, 2006).   
Selective-serotonin re-uptake inhibitors (SSRIs) have been used to treat 
depression for years, but have recently been associated with promoting neurogenesis and 
BDNF production. Studies have shown a marked reduction in neurogenesis when cells 
are damaged within the dentate gyrus in rodents. Chronic treatment with Fluoxetine 
Figure 3.  4 layers of the subventricular zone (I, II, III, IV) 
                  Image from Gonzales-Perez, 2012 
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specifically has been proven to up-regulate neurogenesis in the hippocampus and the 
production of BDNF in rodent studies (Ploughman et al, 2009). Upregulation of BDNF is 
linked to serotonin binding to 5-HT subtype receptors in both the SVZ and SGZ (Benasr 
et al, 2003).  Chollet's recent FLAME study (2011) has shown enhanced motor recovery 
in ischemic stroke patients after chronic fluoxetine treatment. Patient subjects were given 
20 mg fluoxetine to take orally for 90 days. The treatment was started 5-10 days after 
stroke and was coupled with physiotherapy. 
 The drug cocktail in this study developed for delayed post-stroke treatment 
included Simvastatin (statin) and Fluoxetine (SSRI). The final component added was 
Ascorbic acid (Vitamin C), an antioxidant (see Figure 4). Ascorbic acid has been shown 
to enhance the effects of SSRIs that are otherwise very sensitive oxidative degradation 
(Idayu et al, 2010). Furthermore, ascorbic acid increases the effectiveness of statins by 
supporting the endothelial eNOS system that up-regulates BDNF (Chen et al, 2005). The 
majority of neurogenesis studies conducted have focused on the SGZ hippocampal niche. 
Therefore this study will concentrate on the more active SVZ neurogenic niche in rats in 
post-stroke studies. 
Stroke and Animal Model 
 The Middle Cerebral Artery Occlusion (MCAo) is the most common focal 
A	   C	  B	  
Figure 4.  (A) Fluoxetine; (B) Simvastatin; (C) Ascorbic Acid 
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Figure 5.  A schematic representation of the various stroke models presented, induced 
by endothelin-1 Image from Windle et al, 2006 
ischemia model used in young rodents (Windle et al, 2006). A modern approach to create 
this occlusion is by inserting an intraluminal suture through the external carotid artery, 
through the internal carotid artery, and up to the point of MCA opening.  Another method 
involves a craniectomy, electrocoagulation of the MCA, and a final cut of the artery to 
insure occlusion (Macrae et al, 2006). The use of aneurysm clips allows for occlusion 
followed by immediate vascular reperfusion upon removal. The injury caused by 
immediate reperfusion is not completely analogous to reperfusion injury in post-stroke 
patients, which occurs over a timescale of hours. Other disadvantages of MCAo include: 
relatively variability in the amount of injury caused, the ischemic injury sometimes does 
not affect the motor cortex, or other arteries become inadvertently blocked with or 
without MCAo therefore not representing a true MCA infarct (Liu, 2011). Inadvertently 
blocked MCA adjacent arteries can result in feeding difficulties that will affect food and 
drug intake, as well as deterioration of long-term health (Windle et al, 2006). These 
factors can heavily influence outcomes of motor deficit studies. 
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Figure 6. Cortical stroke induced by ET-1 resulted in the 
highest Montoya Staircase deficit both 1 week (A) and 1 
month (B) post-surgery. 
 
Figure 7. Cortical stroke induced by ET-1 resulted in the 
highest % of ipsilateral function 1 week post-surgery (A), 
and remained high 1 month post-surgery (B) 
 
 A less invasive method of inducing stroke are various ways of applying 
Endothelin-1 (ET-1), a potent vasoconstrictor that can produce ischemic injury when 
injected directly into brain tissue. ET-1 injection has shown a more consistent injury 
profile (Soleman et al, 2010) as well as more consistent MCA infarcts (Windle et al, 
2006). ET-1 also allows for reperfusion injury to occur over several hours as opposed to 
clips and sutures that allow for reperfusion almost instantly after removal, thus better 
mimicking a human stroke (Windle et al, 2006). The amount of stroke injury can adjusted 
comparison to MCA infarcts (see Figure 5). Though the topical injection produces more 
concentrated lesions than the 
intracortical injection, the 
intracortical method creates 
lesions large enough for viable 
motor deficits. The “success 
rate” in this study was gauged 
by the number of animals that 
survived stroke induction 
surgery, coupled with a 
minimum of 20% forelimb 
function deficit in the 
Montoya Staircase behavioral 
test. The success rate was 
highest for intracortical 
injection (up to 91% 
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depending on dosage) in comparison to both MCAo (50%) and topical injection (75%). 
The Intracortical injection method is also shown to maintain the highest percentage of 
ipsilateral forelimb function 1-week post-surgery and remains significantly higher than 
the contralateral limb 1-month post-surgery. Also, the percentage of Montoya Staircase 
deficit is highest in the intracortical injection subjects than other methods 1-month post 
surgery. (see Figures 6 & 7). Therefore, intracortical injection using Endothelin-1 
causing a cortical stroke (Windle et al, 2006) was the developed stroke induction model 
modified for use by our 
laboratory.   
 In developing a viable 
animal model, adult rats were 
chosen for the study. This is 
because studies in younger rats 
have shown a near-linear increase 
in motor recovery in control 
models – adults rats do not 
display such rapid recovery rates 
(see Figure 8) (Weissner et al, 
2003). Cultivating this rate of 
improvement in an adult rat could 
be correlated to an increase in 
neurogenesis. Additionally, 
human stroke occurs most often in those above age 55, and adult rat subjects around 1 
Figure 8. Control models show rapid initial      
recovery in motor function in young rats 
Graphs taken from Weissner et al, 2003 
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year old (2 year life-span) would have a greater correlation to the human stroke model 
(Cameron et al, 1982). This is another reason MCAo could not be used; adult rats do not 
sustain a neurogenic growth rate large enough to recover from such a large injury. 
 Sprague Dawley and Long-Evans rats have traditionally been used as Montoya 
Staircase subjects. Sprague Dawley rats were proven to be most successful in achieving 
pre-stroke training criteria when compared to Wistar and Long-Evans rats. Female rats 
were used in the study because they fulfill weight limit criteria for commercial Montoya 
Staircase models – 400 grams). Female weight range is 250-300 grams while males range 
between 450-520 grams. 
 
Drug Delivery Method 
 An administration method had to be developed to effectively deliver the 
Fluoxetine, Simvastatin, and Ascorbic acid drug cocktail to rats. Because drugs were to 
be delivered into the bloodstream daily, an administration method that minimized stress 
was also essential. The physiological effects of stress include anxiety, hypertension and 
other cardiovascular effects, increased susceptibility to infection and other 
immunological effects, and increased levels of glucocorticoids released in the 
bloodstream (NIMH, 2012). Glucocorticoids, especially corticosterone, have been shown 
to inhibit neurogenesis among other neurophysical effects (Cameron et al, 1999). 
 A common method for daily administration of drugs is through subcutaneous 
injection. A recent study compared the effects on corticosteroid levels of subcutaneous 
injection versus oral administration of buprenorphine (Goldkuhl et al, 2008). The results 
showed that oral administration of buprenorphine significantly reduced corticosteroid 
levels while subcutaneous injection subjects showed no reduction in these hormone 
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levels. 
 Oral administration through oral gavage is a commonly used method and has been 
shown to be an effective method of drug delivery. This method, however, has been 
shown to produce esophageal injury as well as restraint related stress during 
administration (Atcha et al, 2010). Studies have shown that voluntary oral administration 
causes less distress and decreased glucocorticoid levels in comparison to using an oral 
gavage. This is especially pertinent for administering the stroke drug cocktail for this 
study because medications must be delivered into the bloodstream daily. 
 Oral administration through syringe or jello (Flecknell et al, 1999) are useful for 
medication that dissolve easily in an aqueous solution or are liquid to begin with. The 
drug cocktail of Fluoxetine, Simvastatin, and Ascorbic acid, however, is lipid soluble 
solid. Therefore, an effective vehicle for administration was found in dissolving the 
powder substance into Pillsbury sugar cookie-dough. Sugar cookie-dough also chosen 
because it was shown to completely absorb lipid-soluble drugs, it could be handled 
easily, and be reliably digested by rodent subjects. Alternative drug-vehicles, such as 
food wafers (Ferguson et al, 2009) were not as reliable throughout the process, from 
handling to drug delivery. Sprague Dawley rats were shown to especially digest the 
cookie-dough with the least failure when compared to other rat strains. In this study, high 
performance liquid chromatography (HPLC) analysis showed serum levels of 
norfluoxetine and fluoxetine 2-4 hours after drug administration (Corbett et al, 2012). 
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MATERIALS AND METHODS 
Experimental Design 
 A total of 51 rat subjects – 44 Sprague Dawley, 7 Long-Evans – were used for 
stroke treatment testing. These two adult rat stocks (10-12 months of age) were chosen 
because of their efficacy in completing Montoya Staircase training (see below). 
 2 drug combination vehicles and 1 vehicle control, making 3 total drug treatment 
groups, were tested over a 1-month period; Drug combination 1:  5 mg/kg fluoxetine, 0.5 
mg/kg simvastatin and 20 mg/kg ascorbic acid (FSA); Drug combination 2:  5 mg/kg 
fluoxetine, 0.5 mg/kg simvastatin (FS); Vehicle control (C). 
  During the endothelin-induced stroke (described below), 2 different sets of 
cortical injection coordinates were used with two injection site in each set; Group 1: (AP: 
0.0 mm, ML: -2.5 mm) and (AP +1.5 mm; ML: -2.5 mm); Group 2: (AP: 0.0 mm, ML: -
2.5mm) and (AP +2.3; ML -2.5 mm). 
 Animal subjects completed Forelimb Asymmetry (described below) and Montoya 
Staircase training within a maximum time of 2 weeks. 20 to 26 hours after stroke 
induction, the first drug vehicle was given through voluntary oral administration. 
Treatment continued daily until 31 days post-stroke, at which time the animal was 
euthanized. Rats were subject to the Forelimb Asymmetry functional test at 3, 16, and 28 
days post-stroke induction. Rats were subject to the Montoya Staircase functional test on 
post-stroke days 8-10 and 29-31. 
 Daily conditions: Rats had ad libitum access to food and water except during 
	   14	  
Montoya Staircase training and functional testing post-stroke. Subjects were housed in 
12-hour light/12-hour dark conditions, which were approved, along with all other animal 
procedures, by the IACUC at Wright State University. 
 
Endothelin-Induced Cortical Stroke 
Procedure prior to Endothelin Injection 
 Anesthesia was induced by inhalation through rodent facial mask of 5% 
isoflurane; concentration was maintained at 2-2.5% throughout the stroke-induction 
surgery. Isoflurane was selected because animal subjects reach the surgical plane for 
anesthesia and recover the quickest from this inhalant in comparison to injectable 
anesthetics such as ketamine. Concentration levels are also more easily changed using the 
inhalant anesthetic versus injectable. 
The rat's head was mounted in a 
stereotactic apparatus that utilizes 
non-traumatic ear bars to reduce 
stress. Puralube ointment was applied 
to the eyes to maintain moisture and 
the head was shaved. The surgical 
site at the top of skull was shaved and 
then cleaned in a 3-step process using 
provoiodine, then 70% ethanaol, and 
finally provoiodine again to insure a clean incision and surgical procedure (as according 
to Wright State Animal-Care Protocol). The analgesic Bupivicaine (0.25%) was applied 
drop-wise to the midline incision in the skin. Unlike most alternative analgesics, 
Figure	  9.	  Orientation	  of	  coordinate	  axes	  
relative	  to	  Bregma	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Bupivicaine acts locally without pervading the systemic circulation. To drill 2 holes in 
the skull, a 0.9 mm burr micro-drill (Fine Science Tools) was used. The drilling 
coordinates for two holes in the skull relative to bregma for Group 1 were (AP: 0.0 mm, 
ML: -2.5 mm) and (AP +1.5 mm; ML: -2.5 mm), and coordinates for Group 2 were (AP: 
0.0 mm, ML: -2.5mm) and (AP +2.3; ML -2.5 mm) (see Figure 9). 
 
Endothelin Injection and Post-Injection Procedure  
 Using a 10 microliter Hamilton syringe, 1 microliter of endothelin solution was 
injected at a depth of 2.3 mm (Long Evans) or 2.0 mm (Sprague Dawley) into the drilled 
holes. The endothelin solution (Human and Porcine ET-1, EMD Chemicals) was 
maintained at a concentration of 400 pmoles/microliter and the injection took place over 
a 2-minute time period (modified from 
procedures described in Windle et al, 2006). 
Vicryl resorbable sutures resealed the incision, 
and the surgical area was again coated with 
provoiodine. Analgesics were not administered 
post-surgery as they have been demonstrated to 
promote or inhibit growth of neural progenitors 
(Hoehn et al, 2005; Sasaki et al, 2003; Sargeant 
et al, 2008). 
 
Voluntary Oral Drug Administration 
 Purchased pharmaceuticals of Simvastatin (80 mg tablet) and Fluoxetine HCl (20 
mg capsule) were used as the primary components for stroke drug treatment. The amount 
of active ingredients within each pharmaceutical correlates to the total drug weight by a 
Figure	  10.	  	  A	  rolled-­‐up	  4	  g	  cookie-­‐
dough	  ball	  (left);	  cookie-­‐dough	  ball	  
with	  depression	  (right)	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specific correction factor; this factor accounts for the amount of “fill” compounds present 
that are inert. For examples, the correction factor for Simvastatin is 10X, and for 
Fluoxetine it is 7.5X using generic drugs – correction factor was recalculated upon every 
new drug purchase. Ascorbic acid (Vitamin C, Fluka) was purchased and administered in 
its pure form. Encapsulated drugs were dumped directly onto the weighing dish; pills 
were first pulverized before weighing. 
 All drugs were encapsulated within a 4 gram Pillsbury sugar cookie-dough “ball”, 
the drug vehicle for voluntary oral administration. A drug-free vehicle was given to the 
rats starting 2 days before surgery, and again after stroke-induction surgery to acclimate 
them to this novel food. Preparation for the cookie-dough “ball” went as follows: 1) the 
4-gram balls were prepared with gloved hands (see Figure 10); 2) a depression within 
each ball was made; 3) the appropriate weight of drugs relative to animal's body mass 
was placed within the depression (Step 3 was skipped for control rat subjects); 4) the 
cookie-dough balls are wrapped and re-rolled up, ensuring a homogenous solid 
containing all medication is created. These cookie-dough balls are placed in each rat cage 
at approximately noon each day of the 31-day stroke treatment regimen. Most often, the 
drug-vehicle was consumed within 10 minutes of presentation. On occasion, consumption 
time would last longer; therefore, the petri-dish in which the drug-vehicle is presented on 
was allowed to sit for 1 full day before being replaced. Remaining drug vehicle that goes 
unconsumed is counted against the total medication consumed; 3 or more days of failing 
to fully consume the drug vehicle was criteria for exclusion from the study. 
 
Montoya Staircase Functional Test 
 The training period for the Montoya Staircase can last a maximum for 2 weeks.  
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The apparatus was set up as shown (see 
Figure 11) with three 50 mg sucrose pellets 
on each well for 7 levels of the staircase 
(both on the right and left sides). Sucrose 
pellets were painted with maple extract and 
allowed to dry prior to placement within the 
apparatus. Training sessions were for a 15-
minute period, once a day, in the 12-hour dark phase. The final 3 days of training were 
used to create the pre-stroke baseline; of these 3 days, the day in which the most pellets 
were retrieved is used. If multiple days showed the same maximum number of pellets 
received but varied between forelimbs, the results were averaged. During this time, 
animal subjects receive a restricted chow diet of 85% of their ad lib feed per day, and 
their weights were not allowed to drop below 90% of their ad lib feeding weight. Any 
animal unable to retrieve 9 pellets total in each forepaw by training termination was 
excluded from functional analysis. 
 Montoya staircase functional testing post-stroke took place for 3 days in the dark-
phase, and was always preceded by an 
overnight fast. Specifically, testing took 
place on days 8-10 and 29-31 post-
stroke. The testing subjects' diets were 
restricted to 10 grams total between the 
drug vehicle and rat chow. Any animal 
unable to retrieve a single pellet during 
Figure	  11.	  Montoya	  Staircase	  
functional	  test	  
Figure	  12.	  Forelimb	  Asymmetry	  
functional	  test	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post-stroke tests was excluded from functional analysis. 
 
 
Forelimb Asymmetry Functional Test 
 This test examines motor deficits within each forepaw by counting the number of 
wall-contacts the rat subject makes with each paw individually over a 5-minute time 
period. The animal was placed into a clear, 9 inch ID acrylic tube, and the subject was 
attracted to the maple extract painted 14 inches from the inside-bottom of the cylinder 
(see Figure 12). To ensure results were accurate, wall contacts were counted from a video 
recording made of each test played back in slow-motion. 
 
 
Euthanization and Cardioperfusion 
 Animals subjects were euthanized 32 days post-stroke induction. The anesthetic 
used was 100 mg/kg pentobarbital (Euthasol), administered via intraperitoneal injection. 
Euthasol was chosen because it puts animals in the surgical plane relatively quickly, 
maintains cardiac function to prevent clotting during perfusion, and enables subjects to 
display the “cardioperfusion dance” (described below). Once the anesthesia was 
appropriately set, cardioperfusion was established with a minimum of 150 mLs PBS 
solution. The PBS solution was then stopped and almost instantly the neural fixative 
solution was perfused. The fixative used was 4% paraformaldehyde in PBS, and a 
minimum of 150 mLs was circulated. A successful cardioperfusion is initially gauged by 
a pale discoloration of the liver as well as a “cardioperfusion dance” in which the rat's 




 Following cardioperfusion, all collected rat brains are immediately placed in 4% 
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paraformaldehyde in PBS blocking solution at 5°C. The brains are postfixed for 24 hours 
in this solution before being transferred into 30% sucrose in PBS at 5°C for 3 days.   
 50 micrometer thick sections were sliced from each rat brain ensuring the entire 
infarct was present somewhere in between the first and last section taken. 1 out of every 3 
sections was retained in PBS solution for estimation of infarct volume.  
 Group 2 Long Evans and Group 1 Sprague Dawley rat infarct section were first 
dried on slides, and then labeled using Nissl stain. This stain labels nissl bodies found 
primarily in the nucleus in the cortex, allowing damaged cells due to stroke to be shown 
in contrast to the remainder of the undamaged section. Stained sections then underwent a 
destaining and dehydration process. Slides were dipped in these solutions sequentially: 
Cresyl Violet (Nissl) stain (15 min), Distilled water (5 min), 70% ethanol (5 min), 95% 
ethanol (5 min), 100% ethanol (5 min), 100% ethanol (5 min), Xylene (5 min), Xylene (5 
min). Nissl stain was created using 2.5 grams of Cresyl Violet dissolved in a 500 mL 
solution made of water (300mL), 1M Na acetate (30 mL), and 1M acetic acid (170 mL). 
The permanent mordant DPX was used to cover-slip the slides. 
 The retained sections from Group 2 Sprague Dawley rats were transferred from 
the PBS solution into PBS containing 1% Triton and 3% donkey serum (serum from host 
of secondary antibody). These sections are reacted with 8-hydroxyguanosine primary 
antibody (1:500 dilution) overnight for about 16 hours (antibody purchased from 
Abcam® company). 8-hydroxyguanosine is a marker of oxidative stress in DNA; it is a 
modified DNA base damaged from hydroxyl radicals produced by oxidative stress 
(Abcam, 2008). The secondary antibody used was a fluorescence label: Donkey Anti-
mouse IgG Rhodamine-X-Red (1:100 dilution), which was interacted with washed 
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sections for 2.5 hours. After a final set of washes, the stained sections were mounted onto 
gel-subbed slides and cover-slipped using Vectashield® to prevent photo-bleaching. 
 
Image Capture and Infarct Volume Calculation 
 The cortical stroke infarct was located and imaged using both the Olympus Epi 
Fluorescence Spot Scope (for Nissl stained sections) and Olympus FV300 Confocal 
Microscope (for 8-hydroxyguanosine stained sections). In cases of large infarcts, multiple 
images were captured and montaged using Adobe Photoshop. 
 Individual infarct areas for each section were calculated using the NIH	   ImageJ 
Program. To calculate an infarct volume, the following steps were followed: 1) Trace the 
infarct area using ImageJ (see Figure 13); 2) Calculate the Infarct Area (mm2); 3) 
Multiply: Infarct Area (mm2) X 0.05 (mm) Section Width = Section Volume; 4) Multiply 
each Section Volume X 3 = Total Section Volume; 5) Sum: ΣTotal Section Volumes = 
Infarct Volume.  
The student t-test was used to analyze the infarct volumes. 
 
 
Figure	  13.	  Infarct	  tracing	  using	  ImageJ	  to	  calculate	  infarct	  area	  of	  a	  section.	  	  
Spot	  Scope	  image,	  Nissl	  stain	  (left);	  Confocal	  image,	  8-­‐hydroxyguanosine	  stain	  (right)	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Statistical Analysis 
Two Way Repeated Measures ANOVA was used to analyze the functional data 
for both Forelimb and Montoya Staircase tests. Post-hoc test varied. To analyze 




 As mentioned previously, any rat subject that failed to fully ingest the drug 
vehicle for 3 days was removed from analysis. Also, subjects that failed to successfully 
retrieve 9 pellets with each paw during Montoya Staircase training were removed. Deficit 
Criteria: Any subject that does not display a minimum 15% functional deficit in 
Forelimb Asymmetry and 15% functional deficit in Montoya Staircase was excluded 




Experimental Design Summary 
 Three different post-stroke medicated treatments were tested; Drug combination 
1:  5 mg/kg fluoxetine, 0.5 mg/kg simvastatin and 20 mg/kg ascorbic acid (FSA); Drug 
combination 2:  5 mg/kg fluoxetine, 0.5 mg/kg simvastatin (FS); Vehicle control (C). In 
addition to testing drug combinations, two different sets of stereotactic coordinates were 
used during endothelin injection. Rats were divided into two groups; Group 1: (AP: 0.0 
mm, ML: -2.5 mm) and (AP +1.5 mm; ML: -2.5 mm); Group 2: (AP: 0.0 mm, ML: -
2.5mm) and (AP +2.3; ML -2.5 mm). The two stocks tested were Sprague Dawley (SD) 
and Long Evans (LE). The infarct volume of each subject was measured after the 31-day 
treatment regimen post-stroke and subsequent euthanization on day 32.  
Forelimb Motor Functional Testing  
 Data was collected for all rats in the study using both the Forelimb Asymmetry 
and Montoya Staircase functional tests (see Tables 1 and 2). Rats were subject to 
Montoya Staircase testing two times during the post-stroke study, aside from pre-stroke 
training. Forelimb Asymmetry testing occurred three times during the post-stroke study. 
 After analyzing post-stroke data, I used Montoya Staircase testing data to study 
deficit correlations with infarct volume because Forelimb Asymmetry data showed 
spontaneous recovery in control rats, with significant improvement in % of contralateral 
limb use 16 and 28 days post-stroke (PS) (see Figure 14). Rapid recovery could be due to 




Figure 14. Forelimb Asymmetry Test Results. Error bars represent SEM.  # indicated 
P<0.05 using Repeated Measures ANOVA and post hoc test.     
 
f 




Figure 15. Infarct Volume Comparison: Group 2 LE rats. Treatment groups: FSA 
(Fluoxetine, Simvastatin, Vit. C), Control. Error bars - SEM 
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Effect of Post-stroke Drug-treatment 
Post-stroke medical treatments were compared by infarct volume in Group 2 
Long Evans rats. The treatment groups tested were FSA and the vehicle control (see 
Figure 15). No significant difference was found between an FSA mean infarct volume of 
5.4696 m3 (SEM = 1.6762) and Control mean infarct volume of 9.6310 m3 (SEM = 
2.6527) (p = 0.221; T-test). 
 Group 2 LE rat treatment groups were separated by rats that met a post-
stroke/pre-stroke deficit criteria of 0.85 (15% forelimb motor deficit) and rats that failed 
Montoya training criteria. FSA and Control groups were separately evaluated, and then 
these two groups were further divided by criteria fulfilled. In Group 2 LE, FSA rats, all 
rats that met training criteria also met deficit criteria (see Figure 16).  The Met All 
Criteria mean infarct volume (6.7380 mm3) was found to be relatively similar to the 
Training Criteria Not Met mean infarct volume  (4.2013 mm3). Statistical analysis could 
not be conducted with sample sizes smaller than N = 3. Also, because rats that did not 
meet training criteria were excluded from the study and therefore functional testing, the 
degree of functional deficit caused by the infarcts could not be determined.  
 The Group 2 LE, Control group was divided by criteria fulfilled (see Figure 17). 
Again, all rats that met training criteria in this group also met the deficit criteria. The Met 
All Criteria mean infarct volume (7.5866 mm3) was relatively similar to the Training 
Criteria Not Met mean infarct volume (13.7198 mm3). Statistical analysis could not be 
conducted because of small sample size; functional deficit caused by infarcts in the 
Training Criteria Not Met group could not be determined. 
 Overall findings suggest that infarct volume does not correlate with post-stroke  
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Figure 17. Infarct Volume Comparison: Group 2 LE, Control rats.  
 28 
 
drug treatment. Data showed that mean infarct volumes in rat treatment groups that met 
and did not meet criteria were relatively similar. Conclusions could not be drawn 
regarding a correlation between infarct size and functional deficit attained because there 
were no rats that met training criteria but failed to meet deficit criteria. 
 A few problems were encountered with the LE rat stock used in these 
experiments. These rats were observed to have a high mortality rate of 25-30% during 
endothelin-induced stroke surgery coupled with a problem in reliably ingesting the drug 
vehicle (significantly different from other rats stocks or strains tested; Chi squared test). 
Furthermore, LE adult rats at 10-12 months were relatively unavailable commercially. 
For these reasons, Sprague Dawley rats were used for the remainder of testing. Post-
stroke medical treatments were compared by infarct volume in Group 2 SD rats. The 
treatment groups tested were FSA and the vehicle control (see Figure 18). No significant 
difference was found between an FSA mean infarct volume of 0.8835 mm3 (SEM = 
0.2165) and Control mean infarct volume of 0.9275 mm3 (SEM = 0.1864) (p = 0.373; T-
test). 
 The Group 2 SD rat treatment group was separated by rats that met a post-
stroke/pre-stroke deficit criteria of 0.85 (15% forelimb motor deficit) and rats that failed 
Montoya training criteria. Each treatment group was looked at individually and each 
group based on criteria fulfilled was compared (see Figure 19). When examining Group 2 
SD, FSA rats, no significant difference was found between the Met All Criteria mean 
infarct volume (1.0630 mm3; SEM = 0.6876), Deficit Criteria Not Met (0.6566 mm3; 
SEM = 0.2576), and Training Criteria Not Met (1.1580 mm3; SEM = 0.3477) (p = 0.390; 
One-way ANOVA). Group 2 SD, Control rat treatment group was separated by rats that  
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Figure 18. Infarct Volume Comparison: Group 2 SD rats. Treatment groups: FSA 




Figure 19. Infarct Volume Comparison:  Group 2 SD, FSA rats.  





Figure 20. Infarct Volume Comparison:  Group 2 SD, Control rats.   




met a post-stroke/pre-stroke deficit criteria of 0.85 (15% forelimb motor deficit) and rats 
that failed Montoya training criteria (see Figure 20). No significant difference was found 
between the Met All Criteria mean infarct volume (1.0425 mm3; SEM = 0.4791), Deficit 
Criteria Not Met (0.6110 mm3), and Training Criteria Not Met (0.9708 mm3; SEM = 
0.0864 mm3) (p = 0.281; One-way ANOVA). 
 Overall findings for Group 2 SD rats suggest that infarct volume does not 
correlate with post-stroke drug treatment. Results show that mean infarct volumes in rat 
groups Met All Criteria versus rats were relatively similar to rat groups Deficit Criteria 
Not Met. This implies that a lack of forelimb motor deficit in some rats was not caused 
by a faulty endothelin injection, but was rather due to a mislocation of the infarct relative 
to the forelimb motor cortex. 
Effect of Rat Stock on Infarct Volume 
 Group 2 SD and LE rats treatment groups were also compared against one 
another, according to infarct volume, to test for a correlation in the infarct induced with 
rat stock used (see Figure 21). As previously described, the two treatment groups tested 
in Group 2 LE and SD rats were FSA and the vehicle control. These findings find a 
significant difference in mean infarct volume between rats stocks in both the FSA (LE = 
5.4696, SEM = 1.6762; SD = 0.8835, SEM = .2165; p = 0.025, T-test) and Control 
groups (LE = 9.6310, SEM = 2.6527; SD = 0.9275, SEM = 0.1864; p = 0.014, T-test). SD 
rats were found to have smaller infarcts induced within both treatment groups. 
 The same comparison as seen in Figure 21 was made, but only using rats that met 
a post-stroke/pre-stroke deficit criteria of 0.85 (15% forelimb motor deficit) (see Figure 
22). Again, the mean infarct volume of FSA-LE (6.7380 mm3; SEM = 1.0571) was found  
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Figure 21. Infarct Volume Comparison: Group 2 LE vs SD rats ;Treatment groups: FSA 





Figure 22. Infarct Volume Comparison: Group 2 LE vs SD rats.  Treatment 
groups: FSA (Fluoxetine, Simvastatin, Vit.C), Control.  Error bars - SEM. 
Excluded – Subjects that failed to meet forelimb motor deficit criteria 
 
   Excluded – Subjects that failed to meet forelimb motor deficit criteria LE bars with N = 2 have no error bars 
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to be significantly less than that of FSA-SD (1.0630 mm3; SEM = 0.6876) (p = 0.017, T-
test). Though the mean infarct volume of Control-LE (7.5866 mm3; SEM = 2.9278) 
seems clearly smaller than that of Control-SD (1.0425 mm3; SEM = 0.4791), this 
difference was not found to be significant (p = 0.133, T-test), most likely due to a small 
sample size and large variability in the infarct volumes. 
 Overall, these findings suggest that endothelin-induced cortical strokes produce a 
significantly larger infarct volume in LE rats in comparison to SD rats. The difference 
seen here can be attributed to the greater number of cerebral collateral vessels found in 
SD rats versus LE rats (Ginsberg, 1989). Collateral vessels allow blood flow to 
circumvent an infarct, thus reducing the total amount of tissue damage caused by the 
ischemic attack.  
 In order to create “LE-sized” infarct volumes within SD rats, different cortical 
injection coordinates must be used in SD rats. Therefore, AP coordinates for one 
injection site were moved, relative to bregma, to +1.5 (Group 1) instead of +2.3 (Group 
2). Thus the two endothelin injection sites were closer to each other for this final group of 
subjects – Group 1 SD rats. 
Effect of Post-stroke Drug Treatment  
 Post-stroke medical treatments were compared by infarct volume in Group 1 SD 
rats. The treatment groups tested were FSA, FS, and the vehicle control (see Figure 23). 
No significant difference was found between any of the groups – an FSA mean infarct 
 36 
volume of 3.4561 mm3 (SEM = 0.5463), an FS mean infarct volume of 2.6579 mm3  
 (SEM = 0.5361), and a Control mean infarct volume of 2.8176 mm3 (SEM = 0.8531) (p 
= 0.612; One-way ANOVA). The Group 1 SD Control group infarct volumes were  
Figure 23. Infarct Volume Comparison: Group 1 SD rats.  Treatment 
groups: FSA (Fluoxetine, Simvastatin, Vit.C), FS (Fluoxetine, Simvastatin), 





Figure 24. Infarct Volume Comparison: Group 1 SD, FSA rats.  





Figure 25. Infarct Volume Comparison: Group 1 SD, FS rats.  




measured outside of this study by Kailee Haggerty, M.S. using 8-hydroxyguanosine 
instead of Nissl stain. 
 Group 1 SD rat treatment group was separated by rats that met a post-stroke/pre-
stroke deficit criteria of 0.85 (15% forelimb motor deficit) and rats that failed Montoya 
training criteria. Each treatment group was looked at separately, and then further divided 
by criteria fulfilled. When examining Group 1 SD, FSA rats, groups were found to be 
relatively similar between the Met All Criteria mean infarct volume (3.7943 mm3; SEM = 
0.7061), Deficit Criteria Not Met (1.6319 mm3), and Training Criteria Not Met (3.9277 
mm3) (see Figure 24).  
 In Group 1 SD, FS rats, mean infarct volumes were again found to be relatively 
similar along all groups (see Figure 25). Mean infarct volume for Met All Criteria was 
2.4364 mm3 (SEM = 0.9031), mean infarct volume for Deficit Criteria Not Met was 
2.5809 mm3 (SEM = 0.7790), and the mean infarct volume for Training Criteria Not Met 
was 4.0733 mm3. Comparing the Met All Criteria and Deficit Criteria groups directly, 
these groups were found to have no significant difference (p = 0.439, T-test). 
 Overall, findings suggest that infarct volume does not correlate with post-stroke 
drug treatment in Group 1 SD rats. Furthermore, results show that mean infarct volumes 
in rat groups Met All Criteria were relatively similar to rat groups Deficit Criteria Not 
Met.  
Effect of Stereotactic Coordinates on Infarct Volume 
 Stereotactic coordinates between Group 1 and Group 2 SD rats were varied at one 
injection site in AP coordinates, +1.5 and +2.3 respectively. The FSA drug group was 
used in both groups in this study; therefore, these groups were used to analyze the effect  
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Figure 26. Infarct Volume Comparison:  Group 1 and 2, SD, FSA rats  
  Group 1 – AP: 0.0 and +1.5 mm; Group 2 – AP: 0.0 and +2.3.  




Figure 27. Infarct Volume Comparison:  Group 1 and 2, SD, FSA rats 
  Group 1 – AP: 0.0 and +1.5 mm; Group 2 – AP: 0.0 and +2.3 
  Excluded – Subjects that failed to meet forelimb motor deficit criteria 
  Error bars - SEM.  
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of stereotactic coordinates on infarct volume (see Figure 26). 
  
 The Group 1, SD, FSA mean infarct volume (3.4561 mm3; SEM = 0.5463) was 
found to be significantly larger than the Group 2, SD, FSA mean infarct volume (0.8835 
mm3; SEM = 0.2165) (p < 0.001).  
 Group 1 and Group 2, SD, FSA rats were compared again, except only using rats 
that met a post-stroke/pre-stroke deficit criteria of 0.85 (15% forelimb motor deficit) (see 
Figure 27). Group 1, SD, FSA rats were found to have a nearly significantly larger mean 
infarct volume (3.7943 mm3; SEM = 0.7061) than that of Group 2, SD, FSA rats (1.0630 
mm3; SEM = 0.6876) (p = 0.057). 
 These results suggest that Group 1 coordinates [(AP: 0.0 mm, ML: -2.5 mm) and 
(AP +1.5 mm; ML: -2.5 mm)] create larger infarcts than Group 2 coordinates [(AP: 0.0 
mm, ML: -2.5mm) and (AP +2.3; ML -2.5 mm)] in SD rats. Larger infarcts can be 
attributed to the fact that Group 1 coordinates are closer to each other than Group 2 
coordinates. Closer injection coordinates may allow the initial growing endothelin-
induced infarcts to coalesce more readily and therefore disrupt a greater number of brain 
vessels, thus creating a larger infarct. 
 
Montoya Deficit vs. Infarct Volume 
 Finally, Montoya Deficit (1 - % Prestroke performance) was plotted against 
infarct volume in all SD rats that met a post-stroke/pre-stroke deficit criteria of 0.85 (15% 
forelimb motor deficit) (see Figure 28) using data from post-stroke day 9. A linear 
regression was calculated using these data points (r2 = 0.632137).   
 Montoya Deficit was again plotted against infarct volume in all SD rats that met a 
post-stroke/pre-stroke deficit criteria of 0.85 (15% forelimb motor deficit) (see Figure 
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29) using data from post-stroke day 30. A linear regression was calculated using these 
data points (r2 = 0.708356). 
 These linear correlations, though only moderately strong, suggest that rat subjects 
who sustained an adequate forelimb motor cortex deficit to meet criteria had infarcts that 
hit at least a portion of the motor cortex. Those animals with larger infarcts that 
correlated with larger deficits could be inferred to have hit more of the motor cortex.  
Those animals with smaller infarcts could be inferred to have hit a smaller portion of the 






Figure 28. Montoya Deficit vs Infarct Volume: Group 1 and 2 SD rats 
  PSD ~ 9; Linear regression shown:  r2 = 0.632137 








































Figure 29. Montoya Deficit vs Infarct Volume: Group 1 and 2 SD rats 
  PSD ~ 30; Linear regression shown:  r2 = 0.708146 























411 ^4.21545 FSA SD PTC-not met  0.8521 1.0542 
412 ^3.64005 FSA SD PTC-not met  0.5592 0.8652 
413 &0.34875 FSA SD 1  1.007 1.0444 
414 *1.5177 FSA SD 0.8235 0.7647 1.0447 1.0755 
415 *3.67845 FSA SD 0.4 0.6 0.5085 0.54901 
417 *5.8479 FS SD 0.4118 0.2941 0.613 0.7783 
418 *1.55325 FS SD 0.6471 0.8823 0.7743 0.9508 
419 ^4.07325 FS SD PTC-not met  0.7367 0.9679 
420 *0.90465 FS SD 0.7429 0.8 0.7996 1.0543 
421 &0.717 FS SD 0.8947 0.7368 0.8328 0.8678 
422 *2.6631 FS SD 0.7778 0.8889 0.9627 1.1828 
423 *1.21305 FS SD 0.7941 0.7647 1.209 1.1717 
424 &1.88025 FS SD 1 1 0.7212 0.7549 
426 &3.74085 FS SD 0.8824 1.0588 0.8933 0.8931 
427 &3.98535 FS SD 1.5833 1.1667 0.7145 0.8145 
428 *2.52285 FSA SD 0.7222 0.7778 0.5455 0.7850 
429 *2.6856 FSA SD 0.7059 0.7059 0.875 1.1683 
430 *5.7639 FSA SD 0 0.2105 0.6635 0.6917 
431 *3.147 FSA SD 0.625 0.6875 0.7274 0.9463 
432 *7.7133 FSA SD 0.375 0.4375 0.7262 0.8732 
433 &2.91495 FSA SD 0.9412 0 0.6929 0.9311 
434 *3.3255 FSA SD 0.6 0.5333 0.6201 0.6360 
 




Group 1 Cortical Injection Coordinates: (AP: 0.0 mm, ML: -2.5 mm) and (AP +1.5 mm; ML: -2.5 mm) 
PSD: Post-stroke Day 
PTC: Pre-stroke Testing Criteria. Rats unable to retrieve a minimum of 9 pellets with each forepaw during 
pre-stroke testing were excluded from the study 
FSA: Fluoxetine, Simvastatin, Ascorbic Acid; FS: Fluoxetine, Simvastatin 
* All Criteria Met 
^ Training Criteria Not Met 


























403 *5.68095 FSA LE 0.3571 0 n/a n/a 
404 *10.5144 C LE 0.2616 0.473684211 n/a n/a 
406 ^13.71975 C LE PTC-not met  0.7726 0.8148 
407 *7.79505 FSA LE 0.6842 0.526315789 0.9257 0.9785 
408 ^7.74 FSA LE PTC-not met  0.9357 0.9682 
409 *4.65885 C LE 0.2 0.2 0.7286 0.4659 
410 ^0.6625 FSA LE PTC-not met  1.181 1.5423 
450 ^0.7758 FSA SD PTC-not met  0.8426 0.7977 
451 *2.45655 C SD 0.8333 0.8889 0.7705 0.7611 
452 *2.43735 FSA SD 0 0.5556 0.6588 0.8850 
453 ^0.7563 C SD PTC-not met  0.6445 0.9014 
455 &0.20955 FSA SD 0.925 0.7 1.1362 1.0299 
456 ^0.91155 C SD PTC-not met  0.7101 0.8587 
457 ^1.07115 C SD PTC-not met  1.1126 1.001 
458 &1.88385 FSA SD 0.8667 0.9333 0.7174 0.9107 
460 *0.5616 C SD 0.7 0.75 0.7342 0.8743 
461 &0.6051 FSA SD 0.8947 0.6842 0.6762 0.9498 
462 *0.78675 C SD 0.825 0.9 0.5504 0.6518 
463 ^1.8522 FSA SD PTC-not met  0.8333 1.0029 
464 *0.36525 C SD 0.8333 0.8333 1.0291 1.1623 
465 *0.3351 FSA SD 0.8095 0.9524 0.8837 0.8165 
467 &0.60855 FSA SD 0.95 0.9 0.7269 0.9660 
468 &0.5097 C SD 0.8889 0.8333 0.8781 0.9553 
469 *0.41655 FSA SD 0.7059 0.7647 0.9332 0.8885 
2470 ^1.1442 C SD PTC-not met  0.8303 0.6727 
471 ^0.846 FSA SD PTC-not met  0.9193 1.0178 
472 &0.7122 C SD 0.95 0.9 1.0674 1.1417 
473 &0.471 FSA SD 0.9474 0.8421 1.088 1.1146 
474 &0.16125 FSA SD 0.9474 0.9474 0.9469 1.0943 
Group 2 Functional Test Data and Deficit Results 
Group 2 Cortical Injection Coordinates: (AP: 0.0 mm, ML: -2.5 mm) and (AP +2.3 mm; ML: -2.5 mm) 
C:Control 
* All Criteria Met 
^ Training Criteria Not Met 









Montoya Staircase vs. Forelimb Asymmetry 
Animal subjects were gauged on whether or not an adequate contralateral forepaw 
motor deficit was attained based on Montoya Staircase functional testing. As mentioned, 
Forelimb Asymmetry functional testing was also conducted for all rats. Forelimb 
Asymmetry data could not be used for this study, however, because of the spontaneous 
recovery observed on post-stroke days 16 and 24 (see Figure 14) with some of the 
infarcts in Sprague Dawley rats.   
I attributed this spontaneous recovery of both control and drug treatment groups 
to the very small infarcts seen post-euthanization in rat subjects, especially Group 2 
Sprague Dawley rats. Smaller infarcts can potentially have a greater chance of preserving 
the specific forelimb function tested in the Forelimb Asymmetry apparatus. The Forelimb 
Asymmetry test is not as rigorous a functional test as the Montoya Staircase – it involves 
less complex motor function to complete the task. Therefore, a valid hypothesis could be 
that Montoya function (grasping and holding) can be more easily altered and less easily 
preserved than Forelimb Asymmetry function. Further testing using a greater number of 
Sprague Dawley rats with larger endothelin-induced infarcts must be conducted to see if 
this theory explains the spontaneous recovery. 
 
Contralateral Forepaw Deficit Criteria 
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Rats had to sustain a 15% contralateral forepaw deficit in Montoya Staircase functional 
testing to fulfill deficit criteria. This deficit criteria was lowered from an original 20% 
deficit because many animals did not sustain an adequate deficit to meet this higher 
criteria. This could again be attributed to the smaller infarcts induced in Group 2 Sprague 
Dawley rats. 
 As the drug-treatment data showed, infarct volumes were relatively similar in 
groups that met and did not meet deficit criteria (see Figures 19, 20, 24, 25). This led to 
the conclusion that an adequate deficit was not attained not because of a faulty endothelin 
injection (too little endothelin injected), but rather a mislocation of the injection site 
relative to the forelimb motor cortex.  A faulty endothelin injection would result in 
significantly smaller induced infarcts in those animals not meeting deficit criteria. A 
mislocation of the infarct could occur for a number of reasons: Bregma, the reference 
point for all coordinates, was not easily identified or was indistinct in some rats; the brain 
underneath the rat skulls (and therefore, the reference marks) may have been slightly 
misaligned relative to each animal; or the injection needle did not penetrate tissue in a 
perfectly vertical plane and thus may have affected a nearby location to the motor cortex. 
A small trend may seem to appear in Figures 19, 20, and 24 suggesting that rats 
not meeting deficit criteria have smaller infarcts. However, in Figure 19, a p-value of 
0.390 clearly indicates no significant difference between any group; in Figures 20 and 24, 
the sample size of N < 3 was too small to conduct statistical analysis or draw any 
conclusions. Figures 19 and 25 have Deficit Criteria Not Met groups that had an adequate 
sample size (N > 2), and in both cases, Deficit Criteria Not Met was found to be clearly 
similar to the Met All Criteria group (p = 0.390 and 0.439, respectively).   
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Group 2 Long Evans rats had no cases that resulted in rats meeting training 
criteria but failing to meet deficit criteria. This could be due to a small sample size (N = 
7), which would imply that there was simply not enough of a chance to have an animal 
that met training but failed deficit criteria. Another theory, however, could be that more 
accurate infarcts hitting the motor cortex, thus inducing an adequate deficit, could be 
attained in Long Evans rats. This could be attributed to a potentially less variable brain-
to-skull alignment, a more distinct bregma reference point, or simply that Long Evans 
rats sustained larger infarcts than Sprague Dawley rats. Further testing using a greater 
number of Long Evans rats is needed to determine the cause. 
Functional tests determining whether or not rats met deficit criteria were 
conducted on days 8, 9, and 10 post-stroke. Perhaps conducting this test closer to the day 
of stroke induction would show more accurately the amount of deficit induced by stroke 
infarct, and would lessen the potential effects of small recovery that may be attained 
during the first ten days post-stroke. 
 
Effect of Rat Stock on Infarct Volume 
 Group 2 coordinates (AP: 0 & +2.3) were initially used for endothelin stroke 
induction surgery in Long Evans rats. These coordinates produced adequately large 
infarcts in this rat stock. However, our laboratory switched to the Sprague Dawley rat 
stock because of the reasons previously mentioned: 1) Sprague Dawley were much easier 
to attain commercially, 2) Long Evans rats had a large mortality rate during stroke 
surgery while Sprague Dawley had only about a 3% mortality, and 3) Sprague Dawley 
rats were shown to ingest the drug vehicle with significantly greater reliability compared 
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to Long Evans and Wistar rat stocks in a study conducted by this lab previously (Corbett 
et al, Laboratory Animals in press).  
 Infarcts sustained in Sprague Dawley rats using Group 2 coordinates were 
significantly smaller than infarcts sustained in Long Evans rats using Group 2 coordinates 
(see Figures 21 & 22). This difference was seen in both FSA and Control groups (p = 
0.014 and 0.025 respectively) and was attributed to the lesser number of collateral vessels 
found in Long Evans versus Sprague Dawley rats (Ginsberg, 1989; Prieto, 2005). An 
occluded vessel may re-route blood flow to smaller surrounding vessels due to increased 
pressure from the blockage. If blood has more avenues through which it can continue 
flowing to the next major vessel, more tissue volume surrounding the occlusion can be 
retained. Greater tissue damage results when blood cannot circumvent an occlusion, thus 
creating a larger sustained infarct.  
 
Stereotactic Coordinates for Endothelin Cortical Injection 
As mentioned, Group 2 coordinates were first used in Long Evans rats, and then 
in Sprague Dawley rats. When it was observed that Sprague Dawley rats sustain much 
smaller infarcts using these cortical injection coordinates, our laboratory changed the AP 
coordinates so that the two injection sites were closer for the Group 1 Sprague Dawley 
rats (Group 1 – AP: 0 & +1.5). The aim was to develop Sprague Dawley infarcts that 
mimicked the Long Evans-sized infarcts seen initially. These closer injection coordinates 
proved to induce significantly larger infarcts than the farther Group 2 coordinates (see 
Figures 26 & 27). An AP coordinate of +1.5 was chosen because this had been 
previously shown to be the center of the forelimb motor cortex (Kleim et al., 1996).  
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A larger infarct may be induced in coordinates that are closer to one another 
because of the greater additive effect of concentration gradients from closer endothelin 
injections. As endothelin perfuses away from the injection site through brain tissue, its 
total concentration decreases with distance, creating a concentration gradient. When the 
injection sites are farther apart, there is a lower total additive concentration when these 
gradients intersect, thus fewer vessels are occluded.  
A future study may look at this overlapping concentration gradient theory by 
moving these closer injection coordinates relative to this “dead-on” forelimb motor 
cortex spot of AP +1.5.  Group 1 coordinates used AP coordinates of 0 and +1.5, with the 
+1.5 being right on the forelimb motor cortex (Kleim et al., 1996). Therefore, the two 
perfusing concentration gradients would coalesce next to but not on this “dead-on” spot.   
A future study could test AP coordinates of +0.75 and +2.25 (“Group 3” 
coordinates), which would contain the dead-on spot right in between and allow the 
gradients to intersect at this spot, making it the center of the large “combined” infarct. If 
more rats are able to meet deficit criteria using these potential Group 3 coordinates versus 
the Group 1 coordinate subjects in this study, this may show that coalescing endothelin 
concentration gradients produce one greater infarct that occludes many vessels. If fewer 
rats are able to meet deficit criteria, this result would suggest coalescing endothelin 
concentration gradients still have a smaller additive effect than a single infarct that is 
placed directly on the motor cortex. 
The ability of intersecting concentration gradients to occlude vessels depends on 
the total endothelin concentration at the edge of the perfusing concentration gradient. 
Suppose the edge has half of the total endothelin concentration – this would suggest that 
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two additive “edges” intersecting would create a fully concentrated endothelin induced 
infarct. Such an infarct would theoretically occlude as many vessels as if there was a 
direct endothelin injection into this “edge - intersecting” area. Suppose the perfusing edge 
has one-fourth the total endothelin concentration – this would suggest the two additive 
“edges” intersecting would sum to only half of the total endothelin concentration. This 
infarct would theoretically occlude fewer vessels and maintain more tissue integrity than 
if each edge made up half of the total concentration.  Essentially, the smaller the 
perfusing gradient (or the greater the total concentration on each “edge”), the greater 
probability of occluding more vasculature, thus creating a larger infarct. 
Furthermore, an observation in this study is that Long Evans rats showed trend 
toward recovery in the FSA group versus Control. Group 2 coordinates used here 
surrounded the forelimb motor cortex, but were not directly on the “dead-on” forelimb 
motor cortex spot of AP +1.5 (Kleim et al., 1996). A theory for why recovery was seen 
here could be the fact that the two coalescing endothelin concentration gradients may 
damage the tissue in between (forelimb motor cortex), but not completely destroy and kill 
it. Images taken to measure the infarct show a clear area beneath the injection site of 
destroyed tissue. Damaged tissue can potentially show a higher propensity for recovery in 
comparison to tissue that is completely dead. 
Montoya Staircase Functional Deficit vs. Infarct Volume 
 Montoya Deficit (1 – Prestroke function %) was plotted against Infarct Volume 
for all Group 1 Sprague Dawley rats that met deficit criteria. Linear trends observed in 
Figures 25 and 26 (r2 = 0.632137 and 0.708146 respectively) suggest that greater infarct 
volumes result in greater Montoya Deficits in rats that met deficit criteria. Specific points 
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to note are rat 430 in Figure 25, and rats 417 and 430 in Figure 26. All three of these data 
points show an infarct volume sustained around 6 mm3 and Montoya Deficit of around 
0.75 or greater.  These infarcts can be determined as “hitting the spot” of the forelimb 
motor cortex. Though rat 432 sustained the largest infarct volume of all Group 1 Sprague 
Dawley rats that met deficit criteria, it did not sustain the greatest Montoya Deficit.  This 
difference implies that the rat 432 infarct was not completely within the forelimb motor 
cortex. Infarcts such as the one seen with rat 432 may explain why these charts in Figure 
25 and 26 do not show a tight correlation (r2 > 0.90) – part of the infarct was not within 
the motor cortex, thus creating a large infarct with a relatively smaller Montoya deficit. 
 
Drug Treatment Effects on Infarct Volume 
Results showed that the drug combinations FSA (fluoxetine, simvastatin, and 
ascorbic acid) and FS (fluoxetine, simvastatin) had no effect on infarct volume when 
compared to Control subjects (see Figures 15, 18, and 23). Infarct volumes for all drug 
and control groups showed no significant difference in all situations where statistical 
analysis could be conducted (N > 2).  
One explanation may the difference in active metabolite enantiomers in the brand 
name fluoxetine (Prozac) versus the generic brand used in Group 2 Sprague Dawley rats. 
Prozac is made up of an approximately 50:50 ratio of R:S fluoxetine enantiomers (Kim, 
2004). The active metabolite of these enantiomers is S-norfluoxetine is shown to be at 
least 20 times more active than its counterpart R-norfluoxetine (McDonagh et al., 2011; 
Kim, 2004). Both R and S-norfluoxetine have been shown to have a half-life of 7 to 15 
days, while R and S-fluoxetine have a half-life of 2 to 4 days (Gury et al., 1999). HPLC 
analysis conducted after this study showed that generic brand fluoxetine had a 15% 
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higher amount of R-fluoxetine and a 15% lower amount of S-fluoxetine in comparison to 
brand name Prozac™ (study was conducted by Audrey McGowin – Chemistry Dept. at 
Wright State University). This would imply that there is a lower amount of the active 
metabolite S-norfluoxetine in the generic fluoxetine used - this may influence the ability 
of generic brand fluoxetine to affect motor deficits in Group 2 Sprague Dawley rats 
because there is less long-lasting active metabolite build-up in the brain. 
Another explanation for the lack of drug effect on infarct volume may simply be 
due to the fact that drugs are not offered for voluntary oral administration until 20-26 
hours after stroke induction. This time lapse may be too great to influence infarct volume 
– perhaps administering drugs sooner could have an effect on the infarct. Further testing 
using a shorter time lapse between stroke induction and voluntary oral drug 
administration would have to be conducted to see if this hypothesis is valid or if the drugs 
were ineffective. 
The ability of statins to improve motor deficits in past studies may also be due to 
upregulation of VEGF along with the previously described upregulation of BDNF. VEGF 
promotes angiogenesis - new vasculature can theoretically help regain function in a 
damaged brain. Studies are currently being conducted in Dr. Corbett’s lab to analyze the 
influence of angiogenesis on motor recovery in rats. 
 
Conclusion 
When endothelin-induced cortical strokes are induced in Long Evans and Sprague 
Dawley rats using Group 2 coordinates [(AP: 0.0 mm, ML: -2.5mm) and (AP +2.3; ML -
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2.5 mm)], Long Evans rats are shown to sustain a significantly larger infarct volume in 
comparison to the Sprague Dawley rat stock. 
 Comparing infarct volumes induced by the closer Group 1 cortical injection 
coordinates [(AP: 0.0 mm, ML: -2.5 mm) and (AP +1.5 mm; ML: -2.5 mm)] in 
comparison to Group 2 coordinates (see above), the closer Group 1 coordinates were 
shown to produce a larger infarct volume in Sprague Dawley rats. 
 Drug treatment groups FSA (fluoxetine, simvastatin, ascorbic acid) and FS 
(fluoxetine and simvastatin) were shown to have no effect on infarct volumes when 
compared, respectively, to the vehicle control.  
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